Mayne Pharma Group Ltd (ASX:MYX)
A$ 4.58 -0.05 (-1.08%) Market Cap: 389.64 Mil Enterprise Value: 279.18 Mil PE Ratio: 0 PB Ratio: 0.83 GF Score: 75/100

Full Year 2022 Mayne Pharma Group Ltd Earnings Call Transcript

Aug 25, 2022 / 11:00PM GMT
Release Date Price: A$6.6 (-4.35%)
Operator

Thank you for standing by, and welcome to the Mayne Pharma FY '22 Results Conference Call and Webcast. (Operator Instructions) I would now like to hand the conference over to Mr. Scott Richards, CEO of Mayne Pharma. Please go ahead.

Scott Anthony Richards
Mayne Pharma Group Limited - MD, CEO & Executive Director

Thank you, and good morning, everybody. Thanks for joining us today to discuss Mayne Pharma's full year results for fiscal 2022. Joining me on the call is Peter Paltoglou, our CFO.

Today, I will provide an update on our business strategy and an overview of the recent transaction we announced to sell Metrics Contract Services to Catalent. Peter will then provide details on the financial results, after which we will open up the call for questions.

Turning now to Slide 4. Just over 2 weeks ago, we announced the acceptance of an offer for Catalent to acquire Metrics for a purchase price of USD 475 million or AUD 679 million. The Board believes this represents compelling value for Mayne Pharma shareholders at approximately 5x revenue

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot